Author:
Lamoureux Francois,Zoubeidi Amina,Gleave Martin E.
Reference368 articles.
1. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2005, Toronto, Canada, 2005.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36.
3. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166:500–6; discussion 506–7.
4. Bruchovsky N, Klotz LH, Sadar M, et al. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol. 2000;4:191–9; discussion 201.
5. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years’ follow-up. Mol Urol. 1999;3:287–92.